Orexigen Therapeutics, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 11, 2010

Attached files

file filename
10-K - FORM 10-K - Orexigen Therapeutics, Inc.d10k.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - Orexigen Therapeutics, Inc.dex311.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - Orexigen Therapeutics, Inc.dex321.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - Orexigen Therapeutics, Inc.dex312.htm
EX-10.23 - BUPROPION HYDROCHLORIDE SUPPLY AGREEMENT - Orexigen Therapeutics, Inc.dex1023.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statements (Form S-3 Nos. 333-159015, 333-160750, and 333-161736) of Orexigen Therapeutics, Inc.,

(2) Registration Statement (Form S-8 No. 333-142405) pertaining to the Orexigen Therapeutics, Inc. 2007 Equity Incentive Plan and 2004 Stock Plan;

of our report dated March 11, 2010, with respect to the financial statements of Orexigen Therapeutics, Inc. and with respect to the effectiveness of internal control over financial reporting of Orexigen Therapeutics, Inc., included in this Annual Report (Form 10-K) of Orexigen Therapeutics, Inc. for the year ended December 31, 2009.

/S/    Ernst & Young LLP

San Diego, California

March 11, 2010

Orexigen Therapeutics, Inc. Reports